Cargando…
Steroid-refractory immune related hepatitis may hide viral re-activation
Cancer immunotherapy has become a stronghold in modern oncology. Immune checkpoint inhibitors, in particular anti-PD-1 and anti-PD-L1 antibodies, are approved for the treatment of several solid cancers. In the near future, an increasing number of patients will be eligible for immunotherapy. Therefor...
Autores principales: | Citarella, Fabrizio, Galletti, Alessandro, Russano, Marco, Gallo, Paolo, Vespasiani-Gentilucci, Umberto, Picardi, Antonio, Tonini, Giuseppe, Vincenzi, Bruno, Santini, Daniele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668132/ https://www.ncbi.nlm.nih.gov/pubmed/33235808 http://dx.doi.org/10.2144/fsoa-2020-0056 |
Ejemplares similares
-
Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020) -
Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019) -
Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021) -
Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020) -
The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention
por: Vespasiani-Gentilucci, Umberto, et al.
Publicado: (2016)